ALTERITY THERAPEUTICS LIMITED - AMERICAN DEPOSITAR

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

04 дек 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

19 ноя 2024 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

12 ноя 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

06 ноя 2024 07:35:00 Источник Nasdaq GlobeNewswire

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

31 окт 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

14 окт 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

11 окт 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

02 окт 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

30 сен 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

23 сен 2024 07:35:00 Источник Nasdaq GlobeNewswire

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

31 июл 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics to Present at MST Financial Webinar

24 июл 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

17 июл 2024 07:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

17 июл 2024 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar

12 июн 2024 19:22:16 Источник Nasdaq GlobeNewswire

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

29 май 2024 19:21:24 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

08 май 2024 07:25:00 Источник Nasdaq GlobeNewswire

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

30 апр 2024 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

29 апр 2024 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

17 апр 2024 07:25:00 Источник Nasdaq GlobeNewswire